Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Seres Therapeutics (MCRB) Equity Ratio: 2015-2025

Historic Equity Ratio for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to 0.30.

  • Seres Therapeutics' Equity Ratio rose 127.60% to 0.30 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.30, marking a year-over-year increase of 127.60%. This contributed to the annual value of 0.10 for FY2024, which is 178.82% up from last year.
  • As of Q3 2025, Seres Therapeutics' Equity Ratio stood at 0.30, which was up 32.92% from 0.23 recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Equity Ratio ranged from a high of 0.47 in Q1 2021 and a low of -0.27 during Q2 2024.
  • For the 3-year period, Seres Therapeutics' Equity Ratio averaged around 0.03, with its median value being 0.06 (2023).
  • The largest annual percentage gain for Seres Therapeutics' Equity Ratio in the last 5 years was 425.37% (2024), contrasted with its biggest fall of 586.36% (2024).
  • Seres Therapeutics' Equity Ratio (Quarterly) stood at 0.37 in 2021, then tumbled by 91.66% to 0.03 in 2022, then tumbled by 504.60% to -0.13 in 2023, then soared by 178.82% to 0.10 in 2024, then spiked by 127.60% to 0.30 in 2025.
  • Its Equity Ratio stands at 0.30 for Q3 2025, versus 0.23 for Q2 2025 and 0.31 for Q1 2025.